Market closed

Marinus Pharmaceuticals/$MRNS

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Marinus Pharmaceuticals

Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.

Ticker

$MRNS

Sector

Health Care

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Radnor, United States

Employees

166

Website

marinuspharma.com

MRNS Metrics

BasicAdvanced

$30M

-

-$2.47

1.26 -

Price and volume

Market cap

$30M

Beta

1.26

52-week high

$10.50

52-week low

$0.22

Average daily volume

2.4M

Financial strength

Current ratio

1.664

Quick ratio

1.334

Long term debt to equity

-143.632

Total debt to equity

-143.632

Interest coverage (TTM)

-7.17%

Management effectiveness

Return on assets (TTM)

-57.97%

Return on equity (TTM)

2,302.56%

Valuation

Price to revenue (TTM)

0.98

Price to book

-0.45

Price to tangible book (TTM)

-0.45

Price to free cash flow (TTM)

-0.266

Growth

Revenue change (TTM)

1.63%

Earnings per share change (TTM)

-6.22%

3-year revenue growth (CAGR)

26.97%

3-year earnings per share growth (CAGR)

-0.18%

What the Analysts think about MRNS

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Marinus Pharmaceuticals stock.

MRNS Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

MRNS Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

MRNS News

AllArticlesVideos

MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNS

Business Wire·1 week ago

Shareholder Alert: Ademi LLP Investigates Whether Marinus Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders

Business Wire·2 weeks ago

MRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Marinus Pharmaceuticals, Inc. Is Fair to Shareholders

Business Wire·2 weeks ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MRNS

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Marinus Pharmaceuticals stock?

Marinus Pharmaceuticals (MRNS) has a market cap of $30M as of January 15, 2025.

What is the P/E ratio for Marinus Pharmaceuticals stock?

The price to earnings (P/E) ratio for Marinus Pharmaceuticals (MRNS) stock is 0 as of January 15, 2025.

Does Marinus Pharmaceuticals stock pay dividends?

No, Marinus Pharmaceuticals (MRNS) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Marinus Pharmaceuticals dividend payment date?

Marinus Pharmaceuticals (MRNS) stock does not pay dividends to its shareholders.

What is the beta indicator for Marinus Pharmaceuticals?

Marinus Pharmaceuticals (MRNS) has a beta rating of 1.26. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.